| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2005 | US20050043224 Administering to patient a pharmaceutical preparation comprising at least one chemoprotective inducing agent and a vehicle for delivering chemoprotective inducing agent to cells lining hair follicles, in an amount and for a time effective to reduce or prevent hair loss |
| 02/24/2005 | US20050043223 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility |
| 02/24/2005 | US20050043222 Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application |
| 02/24/2005 | US20050043214 Antiglaucomatous agent and use thereof |
| 02/24/2005 | US20050043212 Drug design of a preferential enzyme inhibitor of the p38 Mitogen-activated protein kinase alpha isoform |
| 02/24/2005 | US20050042733 Propagating swine mast cells in nutrient broth and recovering mucopolysaccharides/heparin |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042705 Methods for the identification of inhibitors of mannosyltransferase as antibiotics |
| 02/24/2005 | US20050042690 Diagnosis and management of infection caused by chlamydia |
| 02/24/2005 | US20050042671 Modulation of angiogenesis |
| 02/24/2005 | US20050042667 Expression vector comprising nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of immune, hematopoietic, inflammatory and tumor diseases |
| 02/24/2005 | US20050042655 Using hematopoietoic regulatory related polypeptide (HEMA) for use in diagnosis, treatment and prevention of hematopoietic disorders |
| 02/24/2005 | US20050042653 Human transport protein homologs |
| 02/24/2005 | US20050042650 EN2 gene, diagnostic and therapeutic uses thereof |
| 02/24/2005 | US20050042614 Point mutations; dipeptidyl-peptidase inhibitors; kits |
| 02/24/2005 | US20050042354 Antiradicals and fat compositions, foods, drinks, drugs or feeds containing the antiradicals |
| 02/24/2005 | US20050042347 Plant extracts; extraction of oils; skin disorders; antiulcer agents; antiallergens |
| 02/24/2005 | US20050042318 Controlling hormone sensitive diseases; solvent extraction of hops, filtration, desolventizing |
| 02/24/2005 | US20050042317 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/24/2005 | US20050042315 Paget's disease; antitumor agents; osteoporesis; nutrient mixture of plant extract and calcium compound |
| 02/24/2005 | US20050042312 Solubility and Absorption Promoter |
| 02/24/2005 | US20050042311 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells |
| 02/24/2005 | US20050042309 Stabilized compositions containing an oxygen-labile active agent and a plant extract |
| 02/24/2005 | US20050042307 Anticholesterol agents; laxatives |
| 02/24/2005 | US20050042306 Mixture containing plant extract with ascorbic acid, tocotrienol, hydroquinone, ubiquinone, octanoic acid, retinol |
| 02/24/2005 | US20050042304 Novel substituted benzimidazole dosage forms and method of using same |
| 02/24/2005 | US20050042303 Therapeutic protocols |
| 02/24/2005 | US20050042302 Using organic acid salts for lactate degradation |
| 02/24/2005 | US20050042295 Anti-angiogenic compositions and methods of use |
| 02/24/2005 | US20050042294 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 02/24/2005 | US20050042290 Core containing venlafaxine with polymers; overcoated with addition polymer |
| 02/24/2005 | US20050042286 Loratadine; wet granulation; dissolving in mouth; blending of antihistamine with binder and filler |
| 02/24/2005 | US20050042285 Storage stability; mixture containing metal compound, polymer |
| 02/24/2005 | US20050042284 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
| 02/24/2005 | US20050042283 Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| 02/24/2005 | US20050042282 Asthma; respiratory system disorders; gastrointestinal disorders; irritable bowel disorders; antiulcer agents |
| 02/24/2005 | US20050042281 Mixture with buffer and carrier; adjust pH of saliva |
| 02/24/2005 | US20050042280 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 02/24/2005 | US20050042279 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 02/24/2005 | US20050042278 Filling capsules with oil mixture |
| 02/24/2005 | US20050042275 Epothilone compositions |
| 02/24/2005 | US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties |
| 02/24/2005 | US20050042271 Analgesics; antiinflammatory agents; sustained release |
| 02/24/2005 | US20050042268 Administering a hormone and penetration enhancer urea compound |
| 02/24/2005 | US20050042266 Cyanoacrylate compositions containing anti-microbial agent |
| 02/24/2005 | US20050042256 Food mixture; dietetics |
| 02/24/2005 | US20050042249 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 02/24/2005 | US20050042248 Mixture of polyol and insulation agent; gelation; dysmenorrhea |
| 02/24/2005 | US20050042243 Oat extracts: refining, compositions and methods of use |
| 02/24/2005 | US20050042241 Topical analgesic and/or antiinflammatory cream; bursitis, tendonitis; dimethyl sulfoxide and a mixture of pluronic gel and lecithin; allows the longer acting pain relievers ketoprofen and diphenhydramine to reach underlying inflamed tissues |
| 02/24/2005 | US20050042237 Method for administering a spill resistant pharmaceutical system |
| 02/24/2005 | US20050042236 Plant extract active as an immunostimulating agent |
| 02/24/2005 | US20050042233 Stabilized compositions containing an oxygen-labile active agent and a fungal extract |
| 02/24/2005 | US20050042225 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 02/24/2005 | US20050042215 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 02/24/2005 | US20050042213 Administering rhodanine derivative and O,O*-dihydroxybenzenebis(p-amidophenol) derivative; metabolic, neurodegenerative and autoimmune diseases; wound healing, antiinflammatory, and anticarcinogenic agents; atherosclerosis, restenosis, nephropathy |
| 02/24/2005 | US20050042202 Gentamicin, amikacin, tobramycin, netilmicin, cephalosporin, ceftazidine, maxalactam, carbopenem, imipenem, aztreonam, ampicillin, penicillin, ureidopenicillin, augmentin, amphotericin, famvir and/or acyclovir; and Vpr protein, fragment or nucleic acid encoding; systemic inflammatory response syndrome |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042198 Ophthalmic and contact lens wetting solutions |
| 02/24/2005 | US20050042197 2-Alkoxyalkyl cyanoacrylate, absorbable liquid or solid polymeric modifier, and acid stabilizer against premature anionic polymerization comprising phosphorous acid anhydride, pyro- or poly- or phosphoric acid, p-touenesulfonic or methanesulfonic acid or trifluoroacetic acid; seals, hemostatic agents |
| 02/24/2005 | US20050042188 A 4-hydroxy-L-proline alkyl ester; sunscreen agents |
| 02/24/2005 | US20050042182 Topical compositions of urea |
| 02/24/2005 | US20050042180 Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder |
| 02/24/2005 | US20050042179 Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine |
| 02/24/2005 | US20050042177 Nanoparticles with a particle size less than 2 microns, and having a surface stabilizer; improved consistency in bioabsorption |
| 02/24/2005 | US20050042176 Medicaments for inhalation comprising a novel anticholinergic and a steroid |
| 02/24/2005 | US20050042175 Combined doses of formoterol and budesonide |
| 02/24/2005 | US20050042173 Pharmaceuticals, cosmetics or nutraceuticals with a bioadhesive and plasticizer on a biodegradable support for transdermal or transmucosal application |
| 02/24/2005 | US20050042172 Administration of medicaments by vaporisation |
| 02/24/2005 | US20050042171 Only once daily administration of an antispasmodic beta-2 adrenergic agonist and an antiinflammatory corticosteroid; inhalation; salmeterol xinafoate |
| 02/24/2005 | US20050039743 Medicament dispenser |
| 02/24/2005 | DE19828273B4 Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 02/24/2005 | DE10336570A1 New pyrazolidine-1,2-dicarboxamide derivatives, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or tumors |
| 02/24/2005 | DE10335566A1 Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen Azolyl carbinols containing drug derivatives of aryl (or heteroaryl) |
| 02/24/2005 | DE10333497A1 Sustained release composition useful in the treatment of e.g. benign prostatic hyperplasia comprises Tamsulosin core with a coating containing combination of polyvinyl acetate and polyvinyl pyrrolidone |
| 02/24/2005 | DE10333393A1 Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol Transdermal therapeutic system with the active ingredient pramipexole |
| 02/24/2005 | DE10333240A1 Therapy for traumatic injuries or coronary conditions involves use of immunosuppressives or ethyl alcohol infusions, each in addition to conventional therapies |
| 02/24/2005 | DE10330768A1 Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung The use of products derived from extremophilic bacteria osmolytes for the production of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases, as well as a osmolytes containing as active ingredient inhalation device |
| 02/24/2005 | CA2743534A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| 02/24/2005 | CA2577239A1 Nitrogen-containing fused ring compound and use thereof as hiv integraseinhibitor |
| 02/24/2005 | CA2576060A1 Macrolides containing oil-in-water emulsions |
| 02/24/2005 | CA2536961A1 Endoluminal prosthesis comprising a therapeutic agent |
| 02/24/2005 | CA2536518A1 Proteasome inhibitors and methods of using the same |
| 02/24/2005 | CA2536470A1 Pyrrole compositions useful as inhibitors of c-met |
| 02/24/2005 | CA2536140A1 Dosing schedule for erbb2 anticancer agents |
| 02/24/2005 | CA2536073A1 Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| 02/24/2005 | CA2535670A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 02/24/2005 | CA2535652A1 Substituted thiophenes and uses thereof |
| 02/24/2005 | CA2535620A1 6-substituted anilino purines as rtk inhibitors |
| 02/24/2005 | CA2535619A1 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| 02/24/2005 | CA2535618A1 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
| 02/24/2005 | CA2535613A1 Treatment of sleep disorders with cholinesterase inhibitors |
| 02/24/2005 | CA2535554A1 Methods for reducing astringency |
| 02/24/2005 | CA2535483A1 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 02/24/2005 | CA2535451A1 Method of treating viral infections |
| 02/24/2005 | CA2535416A1 Imidazopyridine derivatives |
| 02/24/2005 | CA2535406A1 Gabanergic modulators |
| 02/24/2005 | CA2535242A1 Use of c-kit inhibitors for treating type ii diabetes |
| 02/24/2005 | CA2535178A1 Channel blocking compounds |
| 02/24/2005 | CA2535020A1 Substituted quinolines serving as antimicrobial agents |